Treatment of adult patients with schizophrenia and complex mental health needs - A national clinical guideline

Nordic Journal of Psychiatry

Volumn 70, Issue 3, 2016, Pages 231-240

  Baandrup, Lone ^a   Østrup Rasmussen, Jesper ^b   Klokker, Louise ^c   Austin, Stephen ^d   Bjørnshave, Thomas ^e   Fuglsang Bliksted, Vibeke ^f   Fink Jensen, Anders ^g   Hedegaard Fohlmann, Allan ^h   Peter Hansen, Jens ⁱ   Kristine Nielsen, Malene ^b   Sandsten, Karl Erik ^j   Schultz, Vilhelm ^g   Voss Knude, Susanne ^g   Nordentoft, Merete ^k  

^a Mental Health Centre Glostrup   (Denmark)

^b Danish Health and Medicines Authority   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d Mental Health Centre Nordsjælland   (Denmark)

^e General Practice   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g Mental Health Centre Copenhagen   (Denmark)

^h Frederiksbergpsykologen   (Denmark)

ⁱ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^j Mental Health Centre Hvidovre   (Denmark)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

Clinical guideline; GRADE; meta analysis; quality of evidence; schizophrenia; strength of recommendations

Indexed keywords

CANNABIS; NEUROLEPTIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; COGNITIVE THERAPY; FAMILY THERAPY; HUMAN; MAINTENANCE THERAPY; MENTAL HEALTH; META ANALYSIS (TOPIC); MOTIVATIONAL INTERVIEWING; NEGATIVE SYNDROME; PATIENT PREFERENCE; POSITIVE SYNDROME; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); DENMARK; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; PROCEDURES; PSYCHIATRIC DIAGNOSIS; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; DENMARK; DIAGNOSIS, DUAL (PSYCHIATRY); EVIDENCE-BASED MEDICINE; FAMILY THERAPY; HEALTH SERVICES ACCESSIBILITY; HUMANS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84955188275     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2015.1074285     Document Type: Article

References (80)

1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
2. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J 2010;182:E839-42.
3. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
4. Higgins J, Altman D. Assessing risk of bias in included studies. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2008. pp. 187-241.
5. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
6. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64:395-400.
7. Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology 2013;225:505-18.
8. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophr Bull 2014;40:192-213.
9. Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, et al. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull 2015;41:449-51.
10. Detke HC, Weiden PJ, Llorca P-M, Choukour M, Watson SB, Brunner E, et al. Comparison of olanzapine long-acting injection and oral olanzapine: A 2-year, randomized, open-label study in outpatients with schizophrenia. J Clin Psychopharmacol 2014;34:426-34.
11. Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry 2014;205:135-44.
12. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74:957-65.
13. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9.
14. Arango C, Kirkpatrick B, Buchanan RW. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. J Nerv Ment Dis 2000;188:50-3.
15. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996;153:1625-7.
16. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995;117:417-23.
17. Hinkelmann K, Yassouridis A, Kellner M, Jahn H, Wiedemann K, Raedler TJ. No effects of antidepressants on negative symptoms in schizophrenia. J Clin Psychopharmacol 2013;33:686-90.
18. Iancu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. Psychiatry Res 2010;179:19-23.
19. Jockers-Scherubl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2005;20:27-31.
20. Lee MS, Kim YK, Lee SK, Suh KY. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 1998;18:399-403.
21. Mico U, Bruno A, Pandolfo G, Maria Romeo V, Mallamace D, D'Arrigo C, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011;26:303-10.
22. Mulholland C, Lynch G, King DJ, Cooper SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J Psychopharmacol 2003;17:107-12.
23. Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, et al. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol 2012;32:593-601.
24. Salokangas RK, Saarijarvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996;94:175-80.
25. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992;31:698-704.
26. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: A placebo-controlled study. Int Clin Psychopharmacol 2000;15:257-61.
27. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994;9:281-5.
28. Usall J, Lopez-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, et al. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. J Clin Psychiatry 2014;75:608-15.
29. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2012;5:CD008016.
30. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 2011;72:349-55.
31. Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24.
32. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010;12:000088.
33. Bressi C, Manenti S, Frongia P, Porcellana M, Invernizzi G. Systemic family therapy in schizophrenia: a randomized clinical trial of effectiveness. Psychother Psychosom 2008;77:43-9.
34. Chien WT. Effectiveness of psychoeducation and mutual support group program for family caregivers of chinese people with schizophrenia. Open Nurs J 2008;2:28-39.
35. Chien WT, Lee IY. The schizophrenia care management program for family caregivers of Chinese patients with schizophrenia. Psychiatr Serv 2010;61:317-20.
36. Chien WT, Chan SWC. The effectiveness of mutual support group intervention for Chinese families of people with schizophrenia: a randomised controlled trial with 24-month follow-up. Int J Nurs Stud 2013;50:1326-40.
37. Chien WT, Thompson DR. An RCT with three-year follow-up of peer support groups for Chinese families of persons with schizophrenia. Psychiatr Serv 2013;64:997-1005.
38. Garety PA, Fowler DG, Freeman D, Bebbington P, Dunn G, Kuipers E. Cognitive behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. Br J Psychiatry 2008;192:412-23.
39. Giron M, Fernandez-Yanez A, Mana-Alvarenga S, Molina-Habas A, Nolasco A, Gomez-Beneyto M. Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year randomized controlled study. Psychol Med 2010;40:73-84.
40. Koolaee AK, Etemadi A. The outcome of family interventions for the mothers of schizophrenia patients in Iran. Int J Soc Psychiatry 2010;56:634-46.
41. Kulhara P, Chakrabarti S, Avasthi A, Sharma A, Sharma S. Psychoeducational intervention for caregivers of Indian patients with schizophrenia: a randomised-controlled trial. Acta Psychiatr Scand 2009;119:472-83.
42. Nasr T, Kausar R. Psychoeducation and the family burden in schizophrenia: a randomized controlled trial. Ann Gen Psychiatry 2009;8:17.
43. Navidian A, Kermansaravi F, Rigi SN. The effectiveness of a group psycho-educational program on family caregiver burden of patients with mental disorders. BMC Res Notes 2012;5:399.
44. Ozkan B, Erdem E, Ozsoy SD, Zararsiz G. Effect of psychoeducation and telepsychiatric follow up given to the caregiver of the schizophrenic patient on family burden, depression and expression of emotion. Pak J Med Sci 2013;29:1122-7.
45. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011;168:472-85.
46. NICE. Psychosis and schizophrenia in adults. National Clinical Guideline Number 178. Updated Edition. London: National Institute for Clinical Excellence; 2014.
47. d'Amato T, Bation R, Cochet A, Jalenques I, Galland F, Giraud-Baro E, et al. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Schizophr Res 2011;125:284-90.
48. Dickinson D, Tenhula W, Morris S, Brown C, Peer J, Spencer K, et al. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am J Psychiatry 2010;167:170-80.
49. Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsa F, Lopez-Carrilero R, et al. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res 2012;142:137-44.
50. Garrido G, Barrios M, Penades R, Enriquez M, Garolera M, Aragay N, et al. Computer-assisted cognitive remediation therapy: cognition, self-esteem and quality of life in schizophrenia. Schizophr Res 2013;150:563-9.
51. Gharaeipour M, Scott BJ. Effects of cognitive remediation on neurocognitive functions and psychiatric symptoms in schizophrenia inpatients. Schizophr Res 2012;142:165-70.
52. Lindenmayer J, McGurk SR, Mueser KT, Khan A, Wance D, Hoffman L, et al. A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatr Serv 2008;59:241-7.
53. Lu H, Li Y, Li F, Jiao X, Shi W, Guo K, et al. Randomized controlled trial on adjunctive cognitive remediation therapy for chronically hospitalized patients with schizophrenia. Shanghai Jingshen Yixue 2012;24:149-54.
54. Man DW, Law KM, Chung RC. Cognitive training for Hong Kong Chinese with schizophrenia in vocational rehabilitation. Hong Kong Med J 2012;18(Suppl6):18-22.
55. Poletti S, Anselmetti S, Bechi M, Ermoli E, Bosia M, Smeraldi E, et al. Computer-aided neurocognitive remediation in schizophrenia: durability of rehabilitation outcomes in a follow-up study. Neuropsychol Rehabil 2010;20:659-74.
56. Quee PJ, Stiekema APM, Wigman JTW, Schneider H, van der Meer L, Maples NJ, et al. Improving functional outcomes for schizophrenia patients in the Netherlands using cognitive adaptation training as a nursing intervention - a pilot study. Schizophr Res 2014;158:120-5.
57. Rass O, Forsyth JK, Bolbecker AR, Hetrick WP, Breier A, Lysaker PH, et al. Computer-assisted cognitive remediation for schizophrenia: a randomized single-blind pilot study. Schizophr Res 2012;139:92-8.
58. Royer A, Grosselin A, Bellot C, Pellet J, Billard S, Lang F, et al. Is there any impact of cognitive remediation on an ecological test in schizophrenia? Cogn Neuropsychiatry 2012;17:19-35.
59. Sanchez P, Pena J, Bengoetxea E, Ojeda N, Elizagarate E, Ezcurra J, et al. Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial. Schizophr Bull 2014;40:707-15.
60. Tan BL, King R. The effects of cognitive remediation on functional outcomes among people with schizophrenia: a randomised controlled study. Aust N Z J Psychiatry 2013;47:1068-80.
61. Twamley EW, Savla GN, Zurhellen CH, Heaton RK, Jeste DV. Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis. Am J Psychiatr Rehabil 2008;11:144-63.
62. Velligan DI, Diamond PM, Maples NJ, Mintz J, Li X, Glahn DC, et al. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophr Res 2008;102:312-19.
63. Velligan DI, Diamond PM, Mintz J, Maples N, Li X, Zeber J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull 2008;34:483-93.
64. Kurtz MM, Richardson CL. Social cognitive training for schizophrenia: A meta-analytic investigation of controlled research. Schizophr Bull 2012;38:1092-104.
65. Bechi M, Riccaboni R, Ali S, Fresi F, Buonocore M, Bosia M, et al. Theory of mind and emotion processing training for patients with schizophrenia: preliminary findings. Psychiatry Res 2012;198:371-7.
66. Gil Sanz D, Diego Lorenzo M, Bengochea Seco R, Arrieta Rodriguez M, Lastra Martinez I, Sanchez Calleja R, et al. Efficacy of a social cognition training program for schizophrenic patients: a pilot study. Span J Psychology 2009;12:184-91.
67. Lak DCC, Tsang HWH, Kopelowicz A, Liberman RP. Outcomes of the Chinese basic conversation skill module (CBCSM) for people with schizophrenia having mild to moderate symptoms and dysfunction in Hong Kong. Int J Psychiatry Clin Pract 2010;14:137-44.
68. Roberts DL, Combs DR, Willoughby M, Mintz J, Gibson C, Rupp B, et al. A randomized, controlled trial of social cognition and interaction training (SCIT) for outpatients with schizophrenia spectrum disorders. Br J Clin Psychol 2014;53:281-98.
69. Rus-Calafell M, Gutierrez-Maldonado J, Ortega-Bravo M, Ribas-Sabate J, Caqueo-Urizar A. A brief cognitive-behavioural social skills training for stabilised outpatients with schizophrenia: A preliminary study. Schizophr Res 2013;143:327-36.
70. Sachs G, Winklbaur B, Jagsch R, Lasser I, Kryspin-Exner I, Frommann N, et al. Training of affect recognition (TAR) in schizophrenia - impact on functional outcome. Schizophr Res 2012;138:262-7.
71. Wang Y, Roberts DL, Xu B, Cao R, Yan M, Jiang Q. Social cognition and interaction training for patients with stable schizophrenia in Chinese community settings. Psychiatry Res 2013;210:751-5.
72. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: Systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 2014;204:20-9.
73. Krakvik B, Grawe RW, Hagen R, Stiles TC. Cognitive behaviour therapy for psychotic symptoms: A randomized controlled effectiveness trial. Behav Cognitive Psychother 2013 Oct;41:511-24.
74. Tarrier N, Kelly J, Maqsood S, Snelson N, Maxwell J, Law H, et al. The cognitive behavioural prevention of suicide in psychosis: A clinical trial. Schizophr Res 2014;156:204-10.
75. Hunt Glenn E, Siegfried N, Morley K, Sitharthan T, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2013;10:CD001088.
76. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: A meta-analysis of randomized controlled trials. J Stud Alcohol Drugs 2009;70:516-27.
77. Smedslund G, Berg RC, Hammerstrom KT, Steiro A, Leiknes KA, Dahl HM, et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev 2011;5:CD008063.
78. Dieterich M, Irving CB, Park B, Marshall M. Intensive case management for severe mental illness. Cochrane Database Syst Rev 2010;10:CD007906.
79. Botha UA, Koen L, Galal U, Jordaan E, Niehaus DJ. The rise of assertive community interventions in South Africa: A randomized control trial assessing the impact of a modified assertive intervention on readmission rates; a three year follow-up. BMC Psychiatry 2014;14:56.
80. Malm UI, Ivarsson BA, Allebeck P. Durability of the efficacy of integrated care in schizophrenia: A five-year randomized controlled study. Psychiatr Serv 2014;65:1054-7.